Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2021

STOCK-BASED COMPENSATION

Schedule of Accounting for Stock-Based Compensation


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2021			2020			2021			2020

Employee and director stock option grants:
Research and development		$	62,655		$	22,858		$	133,450		$	50,071
General and administrative			358,506			93,435			612,892			303,010
Total stock-based compensation		$	421,161		$	116,292		$	746,342		$	353,081

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


							Weighted
		Number of					Average
		Shares Issuable					Remaining
		Upon Exercise		Weighted			Contracted		Aggregate
		of Outstanding		Average			Term in		Intrinsic
		Options		Exercise Price			Years		Value
Outstanding at December 31, 2020		1,184,464		$	4.34				$	316,688
Granted		208,500		$	1.78
Outstanding at March 31, 2021		1,392,964		$	3.96		8.56		$	122,700
Granted		3,309,000		$	1.66
Expired		(177)		$	2,800.00
Outstanding at June 30, 2021		4,701,787		$	2.23		9.31		$	—
Granted		20,000		$	1.06
Forfeited		(46,001)		$	2.01
Outstanding at September 30, 2021		4,675,786		$	2.23		9.05		$	—

Exercisable, September 30, 2021		810,100		$	4.87		7.45		$	—
Unvested, September 30, 2021		3,865,686		$	1.68		9.38		$	—

Schedule of Restricted Stock Grants


				Weighted
				Average
				Grant Date			Total Grant
		Number of		Fair Value			Date Fair
		Shares		Per Share			Value
Outstanding at December 31, 2019		9,334		$	21.00		$	196,000
Vested		(9,334)		$	21.00		$	(196,000)
Outstanding at December 31, 2020		—		$	—		$	—